Shiloh
Editor, Senior Moderator
Source: https://www.cidrap.umn.edu/news-perspective/2020/06/stewardship-resistance-scan-jun-17-2020
Stewardship / Resistance Scan for Jun 17, 2020
Antibiotic duration for neonatal sepsis; Funding for rapid resistant-UTI test
Filed Under:
Antimicrobial Stewardship; Diagnostics
Wording change tied to fewer unneeded antibiotics for neonatal sepsis
A change in the wording of antibiotic duration orders for neonatal sepsis led to a substantial decrease in the number of infants who received extra unnecessary antibiotic orders, pharmacists at a hospital in British Columbia reported today in the American Journal of Infection Control.
The intervention implemented at Surrey Memorial Hospital in British Columbia in April 2016 involved a change in the way that clinicians wrote the orders for antibiotic duration in infants with sepsis, from "antibiotics for 48h if blood culture negative" to "antibiotics for 48h unless blood culture positive."
The change in the wording allowed infants to stop receiving antibiotics after they received 48 hours of therapy if the healthcare team had not received notification of a positive culture. The change was made because delays in receiving notification of a negative blood culture can lead to infants receiving extra, unnecessary antibiotic doses.
A medical review of 523 charts (268 prior to the change and 255 after the change) found that unnecessary antibiotic orders (doses beyond 48 hours) were administered to 50% (82 of 164) of infants prior the change and only 7.2% (12/167) after the change. None of the patients included in the review had a blood culture come back positive after the 48 hours of antibiotics were completed. Reductions in pharmacy time and medication waste were also observed.
"The wording and interpretation of antibiotic duration orders, as well as fostering the desired culture shift amongst staff, should be considered as strategies to reduce unnecessary antibiotic administration," the authors of the study wrote.
Jun 17 Am J Infect Control abstract
CARB-X funds rapid test for resistant urinary tract infections
CARB-X today announced that it is awarding India-based Module Innovations a contract worth $702,000 and up to $2.5 million more if it meets certain milestones to develop a rapid diagnostic test for drug-resistant urinary tract infections (UTIs). In a press release, CARB-X said the test would also provide information on which antibiotics would be most useful against the resistant organisms, including common ones such as Escherichia coli, Klebsiella, Pseudomonas aeruginosa, and Enterococci faecalis.
The test has the capacity to take days off the time needed to diagnose a UTI and can detect an infection and provide an antibiotic-resistance profile of the pathogen in about 2 hours. The current process requires advanced microbiology laboratories and personnel, and doctors often prescribe patients broad-spectrum antibiotics while waiting days for a test result. The approach doesn't often work, leading to sepsis, kidney damage, and other complications. CARB-X said the affordable and data-driven approach will be useful, especially in middle- and low-income countries.
Erin Duffy, PhD, chief of research and development at CARB-X, said, "This technology, if successful, could provide health professionals with fast, accurate, and affordable AST [antibiotic susceptibility testing] information for UTIs, accelerating the delivery of effective therapeutics to patients, saving lives, and reducing the risk of contributing to drug resistance."
Since its launch in 2016, CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) has awarded more than $232.1 million to companies developing new treatments and diagnostics for drug-resistant pathogens.
Jun 17 CARB-X press release
Stewardship / Resistance Scan for Jun 17, 2020
Antibiotic duration for neonatal sepsis; Funding for rapid resistant-UTI test
Filed Under:
Antimicrobial Stewardship; Diagnostics
Wording change tied to fewer unneeded antibiotics for neonatal sepsis
A change in the wording of antibiotic duration orders for neonatal sepsis led to a substantial decrease in the number of infants who received extra unnecessary antibiotic orders, pharmacists at a hospital in British Columbia reported today in the American Journal of Infection Control.
The intervention implemented at Surrey Memorial Hospital in British Columbia in April 2016 involved a change in the way that clinicians wrote the orders for antibiotic duration in infants with sepsis, from "antibiotics for 48h if blood culture negative" to "antibiotics for 48h unless blood culture positive."
The change in the wording allowed infants to stop receiving antibiotics after they received 48 hours of therapy if the healthcare team had not received notification of a positive culture. The change was made because delays in receiving notification of a negative blood culture can lead to infants receiving extra, unnecessary antibiotic doses.
A medical review of 523 charts (268 prior to the change and 255 after the change) found that unnecessary antibiotic orders (doses beyond 48 hours) were administered to 50% (82 of 164) of infants prior the change and only 7.2% (12/167) after the change. None of the patients included in the review had a blood culture come back positive after the 48 hours of antibiotics were completed. Reductions in pharmacy time and medication waste were also observed.
"The wording and interpretation of antibiotic duration orders, as well as fostering the desired culture shift amongst staff, should be considered as strategies to reduce unnecessary antibiotic administration," the authors of the study wrote.
Jun 17 Am J Infect Control abstract
CARB-X funds rapid test for resistant urinary tract infections
CARB-X today announced that it is awarding India-based Module Innovations a contract worth $702,000 and up to $2.5 million more if it meets certain milestones to develop a rapid diagnostic test for drug-resistant urinary tract infections (UTIs). In a press release, CARB-X said the test would also provide information on which antibiotics would be most useful against the resistant organisms, including common ones such as Escherichia coli, Klebsiella, Pseudomonas aeruginosa, and Enterococci faecalis.
The test has the capacity to take days off the time needed to diagnose a UTI and can detect an infection and provide an antibiotic-resistance profile of the pathogen in about 2 hours. The current process requires advanced microbiology laboratories and personnel, and doctors often prescribe patients broad-spectrum antibiotics while waiting days for a test result. The approach doesn't often work, leading to sepsis, kidney damage, and other complications. CARB-X said the affordable and data-driven approach will be useful, especially in middle- and low-income countries.
Erin Duffy, PhD, chief of research and development at CARB-X, said, "This technology, if successful, could provide health professionals with fast, accurate, and affordable AST [antibiotic susceptibility testing] information for UTIs, accelerating the delivery of effective therapeutics to patients, saving lives, and reducing the risk of contributing to drug resistance."
Since its launch in 2016, CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) has awarded more than $232.1 million to companies developing new treatments and diagnostics for drug-resistant pathogens.
Jun 17 CARB-X press release